Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

These include FOXD1, a transcription factor that regulates IPF-associated genes such as galectin-3 (30), as well as 2 nuclear receptors, the pregnane X receptor and the vitamin D receptor, both of which can bind DNA as heterodimers with retinoic acid receptors (31 to 34), which are strongly implicated in mucin gene regulation (35, 36).

Source: Annotation of eRNA signatures localizes RNA polymerase II loading to the MUC5B: 3 kb enhancer.. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Cells were cultured at ALI for a minimum of 14 days before processing.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage: and disease-dependent epigenetic remodeling

Study design awaiting verification · JCI Insight · 2021

Original publication title

The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage: and disease-dependent epigenetic remodeling

Fabienne Gally; Sarah K. Sasse; Jonathan S. Kurche; Margaret A. Gruca; Jonathan H. Cardwell; Tsukasa Okamoto; Hong W. Chu; Xiaomeng Hou; Olivier B. Poirion; Justin Buchanan; Sebastian Preissl; Bing Ren; Sean P. Colgan; Robin D. Dowell; Ivana V. Yang; David A. Schwartz; Anthony N. Gerber

© 2021 Gally et al.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The G/T transversion rs35705950, located approximately 3 kb upstream of the MUC5B start site, is the cardinal risk factor for idiopathic pulmonary fibrosis (IPF). Here, we investigate the function and chromatin structure of this: 3 kb region and provide evidence that it functions as a classically defined enhancer subject to epigenetic programming. We use nascent transcript analysis to show that RNA polymerase II loads within 10 bp of the G/T transversion site, definitively establishing enhancer function for the region. By integrating Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analysis of fresh and cultured human airway epithelial cells with nuclease sensitivity data, we demonstrate that this region is in accessible chromatin that affects the expression of MUC5B.

Through applying paired single-nucleus RNA: and ATAC-seq to frozen tissue from IPF lungs, we extend these findings directly to disease, with results indicating that epigenetic programming of the: 3 kb enhancer in IPF occurs in both MUC5B-expressing and nonexpressing lineages. In aggregate, our results indicate that the MUC5B-associated variant rs35705950 resides within an enhancer that is subject to epigenetic remodeling and contributes to pathologic misexpression in IPF.

Authors’ abstract

The G/T transversion rs35705950, located approximately 3 kb upstream of the MUC5B start site, is the cardinal risk factor for idiopathic pulmonary fibrosis (IPF). Here, we investigate the function and chromatin structure of this: 3 kb region and provide evidence that it functions as a classically defined enhancer subject to epigenetic programming. We use nascent transcript analysis to show that RNA polymerase II loads within 10 bp of the G/T transversion site, definitively establishing enhancer function for the region. By integrating Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) analysis of fresh and cultured human airway epithelial cells with nuclease sensitivity data, we demonstrate that this region is in accessible chromatin that affects the expression of MUC5B.

Through applying paired single-nucleus RNA: and ATAC-seq to frozen tissue from IPF lungs, we extend these findings directly to disease, with results indicating that epigenetic programming of the: 3 kb enhancer in IPF occurs in both MUC5B-expressing and nonexpressing lineages. In aggregate, our results indicate that the MUC5B-associated variant rs35705950 resides within an enhancer that is subject to epigenetic remodeling and contributes to pathologic misexpression in IPF.

Publication and source details

Original title: The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage: and disease-dependent epigenetic remodeling

Fabienne Gally; Sarah K. Sasse; Jonathan S. Kurche; Margaret A. Gruca; Jonathan H. Cardwell; Tsukasa Okamoto; Hong W. Chu; Xiaomeng Hou; Olivier B. Poirion; Justin Buchanan; Sebastian Preissl; Bing Ren; Sean P. Colgan; Robin D. Dowell; Ivana V. Yang; David A. Schwartz; Anthony N. Gerber

JCI Insight · 2021

Address correspondence to: Anthony N. Gerber, Department of Medicine, National Jewish Health, Room K729, 1400 Jackson St., Denver, Colorado 80206, USA. Phone: 303.270.2783; Email: gerbera@njhealth.org. Or to: David A. Schwartz, Department of Medicine, University of Colorado, Aurora, Colorado 80045, USA. Phone: 303.724.1783; Email: david.schwartz@ucdenver.edu.

Authorship note: FG and SKS contributed equally to this work.

© 2021 Gally et al.2021Gally et al.https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.U.S. Department of Defensehttps://doi.org/10.13039/100000005W81XWH-17-1-0597National Institutes of Healthhttps://doi.org/10.13039/100000002R01GM125871National Institutes of Healthhttps://doi.org/10.13039/1000000021S10OD012300

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:33:43.754346+00:00

DOI: 10.1172/jci.insight.144294 · PMC7934873